Dermata Therapeutics Inc (DRMA)
1.120
-0.07
(-5.79%)
USD |
NASDAQ |
Nov 15, 16:00
1.12
0.00 (0.00%)
After-Hours: 20:00
Dermata Therapeutics Research and Development Expense (TTM): 5.648M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 5.648M |
| March 31, 2024 | 4.478M |
| December 31, 2023 | 4.070M |
| September 30, 2023 | 3.824M |
| June 30, 2023 | 4.474M |
| March 31, 2023 | 5.248M |
| December 31, 2022 | 5.651M |
| September 30, 2022 | 5.874M |
| Date | Value |
|---|---|
| June 30, 2022 | 5.120M |
| March 31, 2022 | 4.375M |
| December 31, 2021 | 3.459M |
| September 30, 2021 | 2.462M |
| June 30, 2021 | 1.783M |
| March 31, 2021 | 1.327M |
| December 31, 2020 | 1.608M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
1.327M
Minimum
Mar 2021
5.874M
Maximum
Sep 2022
3.96M
Average
4.375M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| NeuroBo Pharmaceuticals Inc | 21.36M |
| Cognition Therapeutics Inc | 45.40M |
| ZyVersa Therapeutics Inc | 2.153M |
| Bone Biologics Corp | 2.618M |
| NovaBay Pharmaceuticals Inc | 0.064M |